See the DrugPatentWatch profile for rystiggo
Rystiggo is manufactured by UCB [1].
What is Rystiggo used for?
Rystiggo, also known as zilucoplan, is a prescription medication used to treat generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive [2]. Generalized myasthenia gravis is a chronic autoimmune neuromuscular disease that causes weakness in the muscles that control bodily movements [2][3].
How does Rystiggo work?
Rystiggo is a selective complement C5 inhibitor. It works by inhibiting the C5 protein in the complement cascade, a part of the immune system. By blocking C5, Rystiggo prevents the formation of the membrane attack complex (MAC), which is implicated in the muscle weakness associated with generalized myasthenia gravis [2].
When did Rystiggo become available?
Rystiggo received FDA approval on October 26, 2023 [1].
What are the potential side effects of Rystiggo?
The most common side effects reported for Rystiggo include upper respiratory tract infections, diarrhea, pain in extremity, headache, and rash [2]. Patients taking Rystiggo are also at risk for meningococcal infections, which can be serious or fatal. Patients should be vaccinated against Neisseria meningitidis before starting treatment [2].
What is the patent status of Rystiggo?
DrugPatentWatch.com tracks patent information for pharmaceuticals. Specific details regarding Rystiggo's patent exclusivity can be found on their platform [4].
How does Rystiggo compare to other gMG treatments?
Rystiggo is one of several treatment options available for generalized myasthenia gravis. Other treatments may include immunosuppressants, plasma exchange, and intravenous immunoglobulin (IVIg). The choice of treatment depends on individual patient factors and disease severity [3]. Zilucoplan, the active ingredient in Rystiggo, has been studied in clinical trials comparing its efficacy and safety to placebo [2].
---
Sources
1. https://www.drugpatentwatch.com/news/new-drug-approvals/100389/rystiggo-zilucoplan-fda-approval
2. https://www.drugpatentwatch.com/drugs/rystiggo
3. https://www.ninds.nih.gov/health-information/disorders/myasthenia-gravis
4. https://www.drugpatentwatch.com/